CBLC 137

Drug Profile

CBLC 137

Alternative Names: CBL-0137; CBLC-137; Curaxin CBL0137

Latest Information Update: 24 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cleveland BioLabs
  • Developer Cleveland BioLabs; Incuron
  • Class Carbazoles; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA intercalators; NF-kappa B inhibitors; SSRP1 protein inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 01 Jan 2017 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater) in USA (IV) (NCT02931110)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Second-line therapy or greater) in Russia (PO)
  • 07 Apr 2016 Pharmacodynamics data from preclinical and in vitro studies in Solid tumours (Combination therapy) presented at the 107th Annual Meeting of American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top